文献速递心律失常

蛋白质组特征用于房颤风险预测

Proteomic Signatures for Risk Prediction of Atrial Fibrillation.
PubMed 文献 · Circulation · 2025-05-22

基于UKB-PPP中51 680名无房颤史个体(1459种血浆蛋白),用lasso-Cox回归在70%随机子集构建蛋白质风险评分,并在剩余30%及ARIC研究中验证。由165种蛋白构成的评分每增加1个标准差,房颤风险比为2.20(95% CI 2.05-2.41);在CHARGE-AF、NT-proBNP和多基因风险评分基础上加入蛋白质风险评分,C指数从0.771升至0.816,5年风险阈值5%时风险重分类为5.4%。

要点

  • 165种血浆蛋白构成的蛋白质风险评分与房颤发生独立相关。
  • 在现有临床和遗传模型上加入蛋白质评分可提升风险预测与重分类。
  • 单次血浆样本的蛋白质组特征或可用于房颤筛查与预防。

核心结论

  • 基于单次血浆样本的蛋白质风险评分可改善房颤风险预测。

研究设计与样本

  • 从UKB-PPP纳入51 680名无房颤史且具有1459种血浆蛋白测量值的个体。
  • 在70%随机子集(36 176人,54.4%女性,2155例事件)用lasso惩罚Cox回归构建蛋白质风险评分,在剩余30%(15 504人,54.4%女性,910例事件)测试。
  • 在ARIC研究(11 012人,54.8%女性,1260例事件)进行外部重复验证。

主要发现

  • UKB-PPP衍生集构建的蛋白质风险评分公式包含165种独特血浆蛋白,其中15种与心房重构相关。
  • 在UKB-PPP测试集中,蛋白质风险评分每增加1个标准差,房颤发生的风险比为2.20(95% CI 2.05-2.41)。
  • 包含CHARGE-AF、NT-proBNP、多基因风险评分和蛋白质风险评分的模型C指数为0.816(95% CI 0.802-0.829),高于不含蛋白质风险评分模型的0.771(95% CI 0.755-0.787),C指数变化为0.044(95% CI 0.039-0.055)。
  • 在CHARGE-AF、NT-proBNP和多基因风险评分基础上加入蛋白质风险评分,5年风险阈值5%时风险重分类为5.4%(95% CI 2.9%-7.9%)。
  • 决策曲线分析中,5年风险阈值5%时,加入蛋白质风险评分前后每1000人的预测净获益分别为3.8和5.4。

临床怎么用

  • 对于无房颤史人群,可考虑在CHARGE-AF、NT-proBNP和多基因风险评分基础上加入蛋白质风险评分以提升风险预测。
  • 蛋白质风险评分可能辅助识别能从房颤筛查和预防策略中获益的个体。

局限性

  • 研究结论基于UKB-PPP和ARIC研究人群,外推至其他人群需谨慎。
  • 研究指出需进一步在房颤筛查和预防中研究蛋白质组特征的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proteomic signatures might improve disease prediction and enable targeted disease prevention and management. We explored whether a protein risk score derived from large-scale proteomics data improves risk prediction of atrial fibrillation (AF). METHODS: A total of 51 680 individuals with 1459 unique plasma protein measurements and without a history of AF were included from the UKB-PPP (UK Biobank Pharma Proteomics Project). A protein risk score was developed with lasso-penalized Cox regression from a random subset of 70% (36 176 individuals, 54.4% women, 2155 events) and was tested on the remaining 30% (15 504 individuals, 54.4% women, 910 events). The protein risk score was externally replicated with the ARIC study (Atherosclerosis Risk in Communities; 11 012 individuals, 54.8% women, 1260 events). RESULTS: The protein risk score formula developed from the UKB-PPP derivation set was composed of 165 unique plasma proteins, and 15 of them were associated with atrial remodeling. In the UKB-PPP test set, a 1-SD increase in protein risk score was associated with a hazard ratio of 2.20 (95% CI, 2.05-2.41) for incident AF. The C index for a model including CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology Atrial Fibrillation), NT-proBNP (N-terminal B-type natriuretic peptide), polygenic risk score, and protein risk score was 0.816 (95% CI, 0.802-0.829) compared with 0.771 (95% CI, 0.755-0.787) for a model including CHARGE-AF, NT-proBNP, and polygenic risk score (C-index change, 0.044 [95% CI, 0.039-0.055]). Protein risk score added to CHARGE-AF, NT-proBNP, and polygenic risk score resulted in a risk reclassification of 5.4% (95% CI, 2.9%-7.9%) with a 5-year risk threshold of 5%. In the decision curve, the predicted net benefit before and after the addition of protein risk score to a model including CHARGE-AF, NT-proBNP, and polygenic risk score was 3.8 and 5.4 per 1000 people, respectively, at a 5-year risk threshold of 5%. External replication of a protein risk score in the ARIC study showed consistent improvement in risk stratification of AF. CONCLUSIONS: Protein risk score derived from a single plasma sample improved risk prediction of AF. Further research using proteomic signatures in AF screening and prevention is needed.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Park H, Norby FL, Kim D, et al. Proteomic Signatures for Risk Prediction of Atrial Fibrillation. Circulation. 2025. PMID: 40401370. doi:10.1161/CIRCULATIONAHA.124.073457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。